A pharmaceutical composition for treating cancer-related fatigue
By leveraging the synergistic effect of the drug combination of isobutyllast and dexamethasone, the problem of the inability to simultaneously control cancer tumor growth and alleviate cancer-related fatigue in existing technologies has been solved, achieving the dual effects of tumor suppression and fatigue improvement while reducing side effects.
CN122398815APending Publication Date: 2026-07-17JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-02
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
There is a lack of effective treatments in the current technology to simultaneously control cancer tumor growth and alleviate cancer-related fatigue. Dexamethasone alone has limited effect on improving cancer-related fatigue and has significant side effects.
Method used
A pharmaceutical composition comprising 89%β94% isotetrastone and 6%β11% dexamethasone, formulated as tablets, capsules or injections, is provided for synergistic inhibition of tumor growth and improvement of cancer-related fatigue.
Benefits of technology
It significantly improves behavioral indicators related to cancer-related fatigue and has a synergistic effect in inhibiting tumor growth and improving fatigue, while reducing side effects and demonstrating good biosafety.
β¦ Generated by Eureka AI based on patent content.
Smart Images
Figure FT_1 
Figure SMS_2 
Figure SMS_4
Abstract
ζ¬εζζΆεδΈη§ζ²»ηηε ζ§η²δΉηθ―η©η»εη©οΌθ―₯θ―η©η»εη©η±ζζζεεε»ε¦δΈε―ζ₯εηθΎ
ζη»ζοΌε
ΆηΉεΎε¨δΊζθΏ°ζζζεη±δ»₯δΈιιηΎεζ―ηεζθ―εΆζοΌεΌδΈεΈηΉ89%ο½94%οΌε°ε‘η±³ζΎ6%ο½11%γζ¬εζζθΏ°ηζζζεζ’θ½ζζζεΆθΏη€ηιΏοΌεθ½ζΎθζΉεηε ζ§η²δΉηΈε
³ηθ‘δΈΊε¦ζζ οΌθδΈε¨ζεΆθΏη€ηιΏεζΉεηε ζ§η²δΉθΏδΈ€ζΉι’ι½ε
·ζεεε’ζδ½η¨γ
Need to check novelty before this filing date? Find Prior Art